Funding

The Aspirin-Exacerbated Respiratory Disease Lab receives ongoing research support from Mayo Clinic, industry and government agencies. Funding sources include:

Investigator & Role	Grant Title	Funding Source	Duration
Elina Jerschow, M.D., M.S., principal investigator; Douglas G. Brownfield, Ph.D., co-principal investigator	Staphylococcus Aureus and Eicosanoid Dysregulation as Drivers of Inflammation in Aspirin-Exacerbated Respiratory Disease	National Institutes of Health — National Institute of Allergy and Infectious Diseases R21AI171306	07/05/2024-05/31/2026
Elina Jerschow, M.D., M.S., principal investigator; Golda Hudes, M.D., co-principal investigator	Effect of 16-Week Dupilumab Treatment on Sinonasal Respiratory Symptoms and Sense of Smell in Ethnically Diverse Patients With Chronic Rhinosinusitis and Nasal Polyposis	Regeneron	01/13/2022-05/01/2026
Elina Jerschow, M.D., M.S., principal investigator; Douglas G. Brownfield, Ph.D., co-principal investigator; Kathryn A. Knoop, Ph.D., co-principal investigator; Erin K. O'Brien, M.D., co-principal investigator; Connie B. Chang, Ph.D., co-principal investigator	Exotoxin-Producing Bacteria Drive Paradoxical Eicosanoid Profile in AERD	Mayo Clinic Center for Clinical and Translational Science-Center for Biomedical Discovery pilot award	01/01/2024-12/31/2024
Elina Jerschow, M.D., M.S., co-principal investigator; Erin K. O'Brien, M.D., co-principal investigator	Identifying Epitopes for Th2A Cells in Nasal Polyps of Patients With AERD	Mayo Clinic Novel Therapeutics and Advanced Diagnostics Award	08/01/2023-12/31/2024
Elina Jerschow, M.D., M.S., principal investigator	Th2A cells mediate outcomes of aspirin-exacerbated respiratory disease (AERD)	National Institutes of Health — National Institute of Allergy and Infectious Diseases R21AI146804	09/03/2020-08/31/2023